AP2015008436A0 - N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group - Google Patents

N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group

Info

Publication number
AP2015008436A0
AP2015008436A0 AP2015008436A AP2015008436A AP2015008436A0 AP 2015008436 A0 AP2015008436 A0 AP 2015008436A0 AP 2015008436 A AP2015008436 A AP 2015008436A AP 2015008436 A AP2015008436 A AP 2015008436A AP 2015008436 A0 AP2015008436 A0 AP 2015008436A0
Authority
AP
ARIPO
Prior art keywords
pyrimidin
pyridin
amine derivatives
derivatives containing
sulfoximine group
Prior art date
Application number
AP2015008436A
Other languages
English (en)
Inventor
Ludwig Zorn
Rolf Bohlmann
Dirk Kosemund
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AP2015008436A0 publication Critical patent/AP2015008436A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2015008436A 2012-11-15 2013-11-13 N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group AP2015008436A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12192855 2012-11-15
PCT/EP2013/073683 WO2014076111A1 (en) 2012-11-15 2013-11-13 N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group

Publications (1)

Publication Number Publication Date
AP2015008436A0 true AP2015008436A0 (en) 2015-05-31

Family

ID=47148673

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008436A AP2015008436A0 (en) 2012-11-15 2013-11-13 N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group

Country Status (27)

Country Link
US (1) US9650361B2 (xx)
EP (1) EP2920164B1 (xx)
JP (1) JP6263194B2 (xx)
KR (1) KR20150082604A (xx)
CN (1) CN104918932B (xx)
AP (1) AP2015008436A0 (xx)
AR (1) AR093503A1 (xx)
AU (1) AU2013346866A1 (xx)
BR (1) BR112015010484A2 (xx)
CA (1) CA2891361C (xx)
CL (1) CL2015001319A1 (xx)
CR (1) CR20150257A (xx)
CU (1) CU20150051A7 (xx)
DO (1) DOP2015000117A (xx)
EA (1) EA201590892A1 (xx)
ES (1) ES2622566T3 (xx)
HK (1) HK1215027A1 (xx)
IL (1) IL238370A0 (xx)
MA (1) MA38091B1 (xx)
MX (1) MX2015006171A (xx)
PE (1) PE20151142A1 (xx)
PH (1) PH12015501076A1 (xx)
SG (1) SG11201503274WA (xx)
TN (1) TN2015000186A1 (xx)
TW (1) TW201418243A (xx)
UY (1) UY35138A (xx)
WO (1) WO2014076111A1 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
WO2014060493A2 (en) * 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
JP2017531003A (ja) 2014-10-16 2017-10-19 バイエル ファーマ アクチエンゲゼルシャフト スルホン基を含有するフッ化ベンゾフラニル−ピリミジン誘導体
JP6671359B2 (ja) * 2014-10-16 2020-03-25 バイエル ファーマ アクチエンゲゼルシャフト スルホキシイミン基を含むフッ素化ベンゾフラニル−ピリミジン誘導体
JP6847099B2 (ja) 2015-09-29 2021-03-24 バイエル ファーマ アクチエンゲゼルシャフト 新規な大環状スルホンジイミン化合物
WO2017060167A1 (en) 2015-10-08 2017-04-13 Bayer Pharma Aktiengesellschaft Novel modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US11254690B2 (en) 2017-03-28 2022-02-22 Bayer Pharma Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
CA3057891A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CA3078583A1 (en) * 2017-10-17 2019-04-25 Merck Patent Gmbh Pyrimidine tbk/ikk.epsilon. inhibitor compounds and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1307271A (en) 1970-06-25 1973-02-14 Shell Int Research Sulphoximine derivatives and their use in herbicidal compositions
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
KR100847169B1 (ko) 2000-12-21 2008-07-17 글락소 그룹 리미티드 혈관형성 조절제로서의 피리미딘아민
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
US7291616B2 (en) 2001-10-31 2007-11-06 Cell Therapeutics, Inc. Aryl triazines as LPAAT-β inhibitors and uses thereof
EP2256108B1 (en) 2002-07-18 2016-03-23 Janssen Pharmaceutica NV Substituted triazine kinase inhibitors
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
JP2006518381A (ja) 2003-02-07 2006-08-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
ATE450517T1 (de) 2004-10-05 2009-12-15 Syngenta Ltd Isoxazolinderivate und ihre verwendung als herbizide
EP1828183A1 (en) 2004-12-17 2007-09-05 AstraZeneca AB 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors
DE102005062742A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
EP1803723A1 (de) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
US20100048597A1 (en) 2006-12-22 2010-02-25 Novartis Ag Organic Compounds and Their Uses
EP2094681A1 (en) 2006-12-22 2009-09-02 Novartis AG Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors
EP3023422A1 (en) 2007-03-12 2016-05-25 YM BioSciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
WO2008129071A1 (en) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
WO2008129080A1 (en) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
WO2008129070A1 (en) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
WO2008132138A1 (en) * 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
EP2303881A2 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
CN102498107A (zh) 2009-09-04 2012-06-13 诺瓦提斯公司 作为激酶抑制剂的杂芳基化合物
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
CN102791697A (zh) 2009-10-12 2012-11-21 瑞科西有限公司 作为TBKL和/或IKKε抑制剂的氨基-嘧啶化合物
CN102933561B (zh) 2010-03-22 2016-05-11 利德发现中心有限责任公司 具有药学活性的二取代三嗪衍生物
DE102010046720A1 (de) * 2010-09-23 2012-03-29 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
KR20130116287A (ko) 2010-11-17 2013-10-23 노파르티스 아게 3-(아미노아릴)-피리딘 화합물
CN103339110A (zh) 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
WO2012101065A2 (en) 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
EP2681193B1 (en) 2011-03-02 2016-01-06 Lead Discovery Center GmbH Pharmaceutically active disubstituted pyridine derivatives
EP2680852A1 (en) 2011-03-02 2014-01-08 Lead Discovery Center GmbH Pharmaceutically active disubstituted triazine derivatives
CA2832919A1 (en) 2011-04-12 2012-10-18 Ryan C. Holcomb Compounds, compositions, and therapeutic uses thereof
CN102731413A (zh) 2011-04-15 2012-10-17 上海医药工业研究院 一种脲类化合物、其制备方法、其中间体及其应用
RU2013151118A (ru) 2011-04-19 2015-05-27 Байер Интеллектуэль Проперти Гмбх Замещенные 4-арил-n-фенил-1,3,5-триазин-2-амины
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
ES2588102T3 (es) * 2011-09-16 2016-10-28 Bayer Intellectual Property Gmbh Derivados de 5-fluoro-pirimidina disustituidos que contienen un grupo sulfoximina
WO2013037896A1 (en) 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro-pyrimidines
WO2014060493A2 (en) * 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
ES2597232T3 (es) 2012-10-18 2017-01-17 Bayer Pharma Aktiengesellschaft 4-(orto)-fluorofenil-5-fluoropirimidin-2-il aminas que contienen un grupo sulfona
DK2928878T3 (en) 2012-11-15 2016-12-19 Bayer Pharma AG 5-Fluoro-N- (pyridin-2-yl) pyridine-2-amine derivatives containing a SULFOXIMINGRUPPE
JP6300818B2 (ja) 2012-11-15 2018-03-28 バイエル ファーマ アクチエンゲゼルシャフト スルホキシイミン基を含有する４−（オルト）−フルオロフェニル−５−フルオロピリミジン−２−イルアミン
CN105492438B (zh) 2013-07-04 2018-08-07 拜耳医药股份有限公司 磺亚胺取代的5-氟-n-(吡啶-2-基)吡啶-2-胺衍生物以及其作为cdk9激酶抑制剂的用途
CN106232596A (zh) 2014-03-13 2016-12-14 拜耳医药股份有限公司 含有砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物

Also Published As

Publication number Publication date
MX2015006171A (es) 2015-08-10
MA38091B1 (fr) 2018-05-31
EP2920164A1 (en) 2015-09-23
SG11201503274WA (en) 2015-06-29
ES2622566T3 (es) 2017-07-06
AR093503A1 (es) 2015-06-10
WO2014076111A1 (en) 2014-05-22
TN2015000186A1 (en) 2016-10-03
BR112015010484A2 (pt) 2017-07-11
DOP2015000117A (es) 2015-06-15
IL238370A0 (en) 2015-06-30
US20150291559A1 (en) 2015-10-15
MA38091A2 (fr) 2016-10-31
KR20150082604A (ko) 2015-07-15
CA2891361A1 (en) 2014-05-22
CU20150051A7 (es) 2015-11-27
CR20150257A (es) 2015-07-01
JP2016501194A (ja) 2016-01-18
CL2015001319A1 (es) 2015-07-17
UY35138A (es) 2014-06-30
CN104918932B (zh) 2017-07-18
HK1215027A1 (zh) 2016-08-12
CN104918932A (zh) 2015-09-16
EP2920164B1 (en) 2017-02-01
EA201590892A1 (ru) 2015-11-30
AU2013346866A1 (en) 2015-05-21
MA38091A3 (fr) 2017-03-31
CA2891361C (en) 2021-07-20
TW201418243A (zh) 2014-05-16
US9650361B2 (en) 2017-05-16
PH12015501076A1 (en) 2015-08-03
PE20151142A1 (es) 2015-08-23
JP6263194B2 (ja) 2018-01-17

Similar Documents

Publication Publication Date Title
HK1213255A1 (zh) 含磺亞胺基的 -氟- 吡啶- -基 吡啶- -胺衍生物
HRP20180672T1 (hr) Novi derivati piridina
HK1215027A1 (zh) 含磺亞胺基團的 吡啶- -基 嘧啶- -胺衍生物
ZA201405486B (en) Pyridone derivatives
IL227664A0 (en) New heterocyclic histories
HK1209414A1 (en) 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group 5--n-(-2-)-2-
HK1215246A1 (zh) 含碸基的 吡啶- -基 嘧啶- -胺衍生物
HK1202544A1 (zh) 芳基乙炔基衍生物
HK1207376A1 (en) Arylethynyl derivatives
HK1206716A1 (en) Novel pyridine derivatives
GB201219689D0 (en) Novel Heteroaromatic derivatives I
GB201119592D0 (en) Novel heteroaromatic Derivatives I
AP2012000567S (en) Packaging anti-mosquitos wristband
GB201214063D0 (en) Packaging fourteen
GB201119594D0 (en) Novel heteroaromatic derivatives II